Oncometabolic Tracks in the Heart

Circulation Research

Volumn 120, Issue 2, 2017, Pages 267-269

  Taegtmeyer, Heinrich ^a   Karlstaedt, Anja ^a   Rees, Meredith L ^a   Davogustto, Giovanni ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

fetal heart; heart; heart failure; isocitrate dehydrogenase; metabolism; neoplasms; pyruvate kinase

Indexed keywords

2 HYDROXYGLUTARIC ACID; DEXTRO 2 HYDROXYGLUTARATE; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

HEART MUSCLE METABOLISM; HEART STRESS; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; NOTE; PRIORITY JOURNAL; ANIMAL; CARDIAC MUSCLE; ENERGY METABOLISM; HEART; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; ENERGY METABOLISM; HEART; HUMANS; MYOCARDIUM; NEOPLASMS;

EID: 85009909969     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310115     Document Type: Note

References (19)

1. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
2. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18:54-61. doi: 10.1016/j.gde.2008.02.003.
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033. doi: 10.1126/science.1160809.
4. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
5. Sen S, Kundu BK, Wu HC, et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc. 2013;2:e004796. doi: 10.1161/JAHA.113.004796.
6. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y, Zhao S, Ye D, Xiong Y, Guan KL. Inhibition of KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26:1326-1338. doi: 10.1101/gad.191056.112.
7. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744. doi: 10.1038/nature08617.
8. Karlstaedt A, Zhang X, Vitrac H, Harmancey R, Vasquez H, Wang JH, Goodell MA, Taegtmeyer H. Oncometabolite d-2-hydroxyglutarate impairs alpha-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc Natl Acad Sci USA. 2016;113:10436-10441.
9. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol. 1994;19:59-113.
10. Hensley CT, Faubert B, Yuan Q, et al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164:681-694. doi: 10.1016/j.cell.2015.12.034.
11. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-233. doi: 10.1038/nature06734.
12. Rees ML, Subramaniam J, Li Y, Hamilton DJ, Frazier OH, Taegtmeyer H. A PKM2 signature in the failing heart. Biochem Biophys Res Commun. 2015;459:430-436. doi: 10.1016/j.bbrc.2015.02.122.
13. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293. doi: 10.1016/j.cell.2012.03.017.
14. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F, Krishnan J, Lerch R, Hall MN, Rüegg MA, Pedrazzini T, Brink M. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011;123:1073-1082. doi: 10.1161/CIRCULATIONAHA.110.977066.
15. Yano T, Shimoshige S, Miki T, Tanno M, Mochizuki A, Fujito T, Yuda S, Muranaka A, Ogasawara M, Hashimoto A, Tsuchihashi K, Miura T. Clinical impact of myocardial mTORC1 activation in nonischemic dilated cardiomyopathy. J Mol Cell Cardiol. 2016;91:6-9. doi: 10.1016/j. yjmcc.2015.12.022.
16. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050-3055. doi: 10.1161/01.CIR.0000130641. 08705.45.
17. Sciarretta S, Zhai P, Maejima Y, Del Re DP, Nagarajan N, Yee D, Liu T, Magnuson MA, Volpe M, Frati G, Li H, Sadoshima J. mTORC2 regulates cardiac response to stress by inhibiting MST1. Cell Rep. 2015;11:125-136. doi: 10.1016/j.celrep.2015.03.010.
18. Shende P, Xu L, Morandi C, Pentassuglia L, Heim P, Lebboukh S, Berthonneche C, Pedrazzini T, Kaufmann BA, Hall MN, Rüegg MA, Brink M. Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy. Cardiovasc Res. 2016;109:103-114. doi: 10.1093/cvr/cvv252.
19. Bénard L, Oh JG, Cacheux M, Lee A, Nonnenmacher M, Matasic DS, Kohlbrenner E, Kho C, Pavoine C, Hajjar RJ, Hulot JS. Cardiac Stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling. Circulation. 2016;133:1458-1471; discussion 1471. doi: 10.1161/CIRCULATIONAHA.115.020678.